gabapentin has been researched along with Alloxan Diabetes in 28 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy." | 7.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| "The present study examines the effect of combinations of gabapentin (Neurontin) and a selective neurokinin (NK)(1) receptor antagonist, 1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-benzofuranylmethyl ester (CI-1021), in two models of neuropathic pain." | 7.71 | Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. ( Field, MJ; Gonzalez, MI; Singh, L; Tallarida, RJ, 2002) |
| "Neuropathic vulvodynia is a state of vulval discomfort characterized by a burning sensation, diffuse pain, pruritus or rawness with an acute or chronic onset." | 5.42 | A streptozotocin-induced diabetic neuropathic pain model for static or dynamic mechanical allodynia and vulvodynia: validation using topical and systemic gabapentin. ( Abbas, M; Ali, G; Sewell, RD; Shahid, M; Subhan, F; Zeb, J, 2015) |
| "Here, we tested the effect of FK1706 on painful diabetic neuropathy in rat model of diabetes induced by streptozotocin (STZ)." | 5.35 | FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy. ( Matsuoka, N; Murai, N; Mutoh, S; Price, RD; Yamaji, T; Yamamoto, H; Yamazaki, S, 2008) |
| "Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy." | 3.76 | Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain. ( Cooke, I; Goodchild, CS; Kolosov, A, 2010) |
| "The present study examines the effect of combinations of gabapentin (Neurontin) and a selective neurokinin (NK)(1) receptor antagonist, 1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-benzofuranylmethyl ester (CI-1021), in two models of neuropathic pain." | 3.71 | Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. ( Field, MJ; Gonzalez, MI; Singh, L; Tallarida, RJ, 2002) |
| "Von Frey filaments were used to assess tactile allodynia." | 1.48 | Evaluation of the neonatal streptozotocin model of diabetes in rats: Evidence for a model of neuropathic pain. ( Barragán-Iglesias, P; Delgado-Lezama, R; Granados-Soto, V; Hong, E; Loeza-Alcocer, E; Oidor-Chan, VH; Pineda-Farias, JB; Price, TJ; Salinas-Abarca, AB; Sánchez-Mendoza, A; Velazquez-Lagunas, I, 2018) |
| "The treatment with gabapentin or LLLT significantly decreased the raised level in total cholesterol in DNP but could not decrease the elevated level of triglycerides, while LDL cholesterol decreased significantly in DNP treated with gabapentin but not affected by LLLT." | 1.48 | Efficiencies of Low-Level Laser Therapy (LLLT) and Gabapentin in the Management of Peripheral Neuropathy: Diabetic Neuropathy. ( Abdel-Wahhab, KG; Daoud, EM; El Gendy, A; Mannaa, FA; Mourad, HH; Saber, MM, 2018) |
| " Pharmacokinetic analysis was based on plasma and urine data concentrations." | 1.48 | The role of organic cation transporter 2 inhibitor cimetidine, experimental diabetes mellitus and metformin on gabapentin pharmacokinetics in rats. ( Baviera, AM; Benzi, JRL; de Moraes, NV; Stevens, JH; Yamamoto, PA, 2018) |
| "Using 3 rat models of neuropathic pain of toxic (oxaliplatin/OXA), metabolic (streptozocin/STZ), and traumatic (sciatic nerve ligation/CCI [chronic constriction nerve injury]) etiologies, we investigated the antihypersensitivity effect of acute and repeated agomelatine administration." | 1.46 | Agomelatine: a new opportunity to reduce neuropathic pain-preclinical evidence. ( Authier, N; Bertrand, M; Chapuy, E; Chenaf, C; Courteix, C; Eschalier, A; Gabriel, C; Libert, F; Marchand, F; Mocaër, E, 2017) |
| "Neuropathic vulvodynia is a state of vulval discomfort characterized by a burning sensation, diffuse pain, pruritus or rawness with an acute or chronic onset." | 1.42 | A streptozotocin-induced diabetic neuropathic pain model for static or dynamic mechanical allodynia and vulvodynia: validation using topical and systemic gabapentin. ( Abbas, M; Ali, G; Sewell, RD; Shahid, M; Subhan, F; Zeb, J, 2015) |
| "Koumine treatment of diabetic rats decreased neuropathic pain behavior as early as after the first administration." | 1.40 | Anti-allodynic and neuroprotective effects of koumine, a Benth alkaloid, in a rat model of diabetic neuropathy. ( Huang, HH; Ling, Q; Liu, M; Wu, MX; Xu, Y; Yang, J; Yu, CX, 2014) |
| "Neuropathic pain is currently an insufficiently treated clinical condition." | 1.40 | Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy. ( Hammock, BD; Inceoglu, B; Wagner, K; Yang, J, 2014) |
| "The threshold of mechanical hyperalgesia was also significantly elevated." | 1.38 | Protective effects of combined therapy of gliclazide with curcumin in experimental diabetic neuropathy in rats. ( Ahmed, AA; Al-Rasheed, NM; Attia, HN; Kenawy, SA; Maklad, YA, 2012) |
| " Analysis of the log dose-response curves for oxcarbazepine or gabapentin in a presence of amitriptyline and oxcarbazepine or gabapentin applied alone, revealed a synergism in oxcarbazepine-amitriptyline and additivity in gabapentin-amitriptyline combination." | 1.36 | Analysis of the antinociceptive interactions in two-drug combinations of gabapentin, oxcarbazepine and amitriptyline in streptozotocin-induced diabetic mice. ( Bosković, B; Micov, AM; Prostran, MS; Stepanović-Petrović, RM; Tomić, MA; Ugresić, ND; Vucković, SM, 2010) |
| "Here, we tested the effect of FK1706 on painful diabetic neuropathy in rat model of diabetes induced by streptozotocin (STZ)." | 1.35 | FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy. ( Matsuoka, N; Murai, N; Mutoh, S; Price, RD; Yamaji, T; Yamamoto, H; Yamazaki, S, 2008) |
| " Here we determined the antinociceptive effect of chronic administration of neramexane and compared its effect with that of memantine and gabapentin in a rat model of diabetic neuropathic pain." | 1.35 | Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain. ( Chen, SR; Pan, HL; Samoriski, G, 2009) |
| "Pretreatment with gabapentin prevented the upregulation of GFAP, S100B, and NSE in all brain regions of diabetic rats." | 1.33 | Novel role for gabapentin in neuroprotection of central nervous system in streptozotocine-induced diabetic rats. ( Baydas, G; Donder, E; Sonkaya, E; Tuzcu, M; Yasar, A, 2005) |
| " There is also a fairly broad consensus that gabapentin is safe and well tolerated, but the side-effect profile of gabapentin has not been adequately assessed in pain populations." | 1.33 | Adverse effects of gabapentin and lack of anti-allodynic efficacy of amitriptyline in the streptozotocin model of painful diabetic neuropathy. ( Bourin, C; Chen, P; Hogan, JB; Leet, JE; Lindner, MD; Machet, F; McElroy, JF; Stock, DA, 2006) |
| "Gabapentin displays efficacy against abnormal sensory processing in diabetic rats and may be of benefit for treating painful diabetic neuropathy." | 1.30 | Gabapentin prevents hyperalgesia during the formalin test in diabetic rats. ( Calcutt, NA; Ceseña, RM, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.14) | 18.2507 |
| 2000's | 7 (25.00) | 29.6817 |
| 2010's | 18 (64.29) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Asfour, HZ | 1 |
| Alhakamy, NA | 1 |
| Ahmed, OAA | 1 |
| Fahmy, UA | 1 |
| Md, S | 1 |
| El-Moselhy, MA | 1 |
| Rizg, WY | 1 |
| Alghaith, AF | 1 |
| Eid, BG | 1 |
| Abdel-Naim, AB | 1 |
| Stepanović-Petrović, R | 1 |
| Micov, A | 1 |
| Tomić, M | 1 |
| Pecikoza, U | 1 |
| Barragán-Iglesias, P | 1 |
| Oidor-Chan, VH | 1 |
| Loeza-Alcocer, E | 1 |
| Pineda-Farias, JB | 1 |
| Velazquez-Lagunas, I | 1 |
| Salinas-Abarca, AB | 1 |
| Hong, E | 1 |
| Sánchez-Mendoza, A | 1 |
| Delgado-Lezama, R | 1 |
| Price, TJ | 1 |
| Granados-Soto, V | 1 |
| Abdel-Wahhab, KG | 1 |
| Daoud, EM | 1 |
| El Gendy, A | 1 |
| Mourad, HH | 1 |
| Mannaa, FA | 1 |
| Saber, MM | 1 |
| Benzi, JRL | 1 |
| Yamamoto, PA | 1 |
| Stevens, JH | 1 |
| Baviera, AM | 1 |
| de Moraes, NV | 1 |
| Ola, MS | 1 |
| Alhomida, AS | 1 |
| LaNoue, KF | 1 |
| García-Hernández, L | 1 |
| Navarrete-Vázquez, G | 1 |
| González-Trujano, ME | 1 |
| López-Muñoz, FJ | 1 |
| Déciga-Campos, M | 1 |
| Ling, Q | 1 |
| Liu, M | 1 |
| Wu, MX | 1 |
| Xu, Y | 1 |
| Yang, J | 3 |
| Huang, HH | 1 |
| Yu, CX | 1 |
| Wagner, K | 1 |
| Inceoglu, B | 2 |
| Hammock, BD | 2 |
| Ali, G | 1 |
| Subhan, F | 1 |
| Abbas, M | 1 |
| Zeb, J | 1 |
| Shahid, M | 1 |
| Sewell, RD | 1 |
| Reda, HM | 1 |
| Zaitone, SA | 1 |
| Moustafa, YM | 1 |
| Chenaf, C | 1 |
| Chapuy, E | 1 |
| Libert, F | 1 |
| Marchand, F | 2 |
| Courteix, C | 1 |
| Bertrand, M | 1 |
| Gabriel, C | 1 |
| Mocaër, E | 1 |
| Eschalier, A | 1 |
| Authier, N | 1 |
| Newton, VL | 1 |
| Guck, JD | 1 |
| Cotter, MA | 1 |
| Cameron, NE | 1 |
| Gardiner, NJ | 1 |
| Yamazaki, S | 1 |
| Yamaji, T | 1 |
| Murai, N | 1 |
| Yamamoto, H | 1 |
| Price, RD | 1 |
| Matsuoka, N | 1 |
| Mutoh, S | 1 |
| Wodarski, R | 1 |
| Clark, AK | 1 |
| Grist, J | 1 |
| Malcangio, M | 1 |
| Chen, SR | 1 |
| Samoriski, G | 1 |
| Pan, HL | 1 |
| Tomić, MA | 1 |
| Vucković, SM | 1 |
| Stepanović-Petrović, RM | 1 |
| Micov, AM | 1 |
| Ugresić, ND | 1 |
| Prostran, MS | 1 |
| Bosković, B | 1 |
| Morgado, C | 1 |
| Terra, PP | 1 |
| Tavares, I | 1 |
| Kolosov, A | 1 |
| Goodchild, CS | 1 |
| Cooke, I | 1 |
| Ortiz, MI | 1 |
| Ponce-Monter, HA | 1 |
| Fernández-Martínez, E | 1 |
| Macías, A | 1 |
| Rangel-Flores, E | 1 |
| Izquierdo-Vega, JA | 1 |
| Sánchez-Gutiérrez, M | 1 |
| Attia, HN | 1 |
| Al-Rasheed, NM | 2 |
| Maklad, YA | 1 |
| Ahmed, AA | 1 |
| Kenawy, SA | 1 |
| Wagner, KM | 1 |
| Bettaieb, A | 1 |
| Schebb, NH | 1 |
| Hwang, SH | 1 |
| Morisseau, C | 1 |
| Haj, FG | 1 |
| Field, MJ | 2 |
| Gonzalez, MI | 1 |
| Tallarida, RJ | 1 |
| Singh, L | 2 |
| Maneuf, YP | 1 |
| Blake, R | 1 |
| Andrews, NA | 1 |
| McKnight, AT | 1 |
| Baydas, G | 1 |
| Sonkaya, E | 1 |
| Tuzcu, M | 1 |
| Yasar, A | 1 |
| Donder, E | 1 |
| Lindner, MD | 1 |
| Bourin, C | 1 |
| Chen, P | 1 |
| McElroy, JF | 1 |
| Leet, JE | 1 |
| Hogan, JB | 1 |
| Stock, DA | 1 |
| Machet, F | 1 |
| Ceseña, RM | 1 |
| Calcutt, NA | 1 |
| McCleary, S | 1 |
| Hughes, J | 1 |
28 other studies available for gabapentin and Alloxan Diabetes
| Article | Year |
|---|---|
Enhanced healing efficacy of an optimized gabapentin-melittin nanoconjugate gel-loaded formulation in excised wounds of diabetic rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Collagen; Diabetes Mellitus, Experimental; Gabapent | 2022 |
Levetiracetam synergizes with gabapentin, pregabalin, duloxetine and selected antioxidants in a mouse diabetic painful neuropathy model.
Topics: Amines; Analgesics; Animals; Anticonvulsants; Antioxidants; Cyclohexanecarboxylic Acids; Diabetes Me | 2017 |
Evaluation of the neonatal streptozotocin model of diabetes in rats: Evidence for a model of neuropathic pain.
Topics: Activating Transcription Factor 3; Amines; Animals; Animals, Newborn; Astrocytes; Cyclohexanecarboxy | 2018 |
Efficiencies of Low-Level Laser Therapy (LLLT) and Gabapentin in the Management of Peripheral Neuropathy: Diabetic Neuropathy.
Topics: Amines; Animals; Combined Modality Therapy; Creatinine; Cyclohexanecarboxylic Acids; Cytokines; Diab | 2018 |
The role of organic cation transporter 2 inhibitor cimetidine, experimental diabetes mellitus and metformin on gabapentin pharmacokinetics in rats.
Topics: Amines; Animals; Cimetidine; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Gabapenti | 2018 |
Gabapentin Attenuates Oxidative Stress and Apoptosis in the Diabetic Rat Retina.
Topics: Amino Acids; Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Disease Mode | 2019 |
Antihyperalgesic activity of a novel synthesized analogue of lidocaine in diabetic rats.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Diabetes Complications; | 2013 |
Anti-allodynic and neuroprotective effects of koumine, a Benth alkaloid, in a rat model of diabetic neuropathy.
Topics: Amines; Animals; Blood Glucose; Body Weight; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experim | 2014 |
Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy.
Topics: Amines; Analgesics; Animals; Benzoates; Chronic Pain; Conditioning, Psychological; Cyclohexanecarbox | 2014 |
A streptozotocin-induced diabetic neuropathic pain model for static or dynamic mechanical allodynia and vulvodynia: validation using topical and systemic gabapentin.
Topics: Administration, Topical; Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Diabetes Mellitus | 2015 |
Effect of levetiracetam versus gabapentin on peripheral neuropathy and sciatic degeneration in streptozotocin-diabetic mice: Influence on spinal microglia and astrocytes.
Topics: Amines; Animals; Astrocytes; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Diabetes | 2016 |
Agomelatine: a new opportunity to reduce neuropathic pain-preclinical evidence.
Topics: Acetamides; Adrenergic alpha-2 Receptor Antagonists; Amines; Animals; Antineoplastic Agents; Constri | 2017 |
Neutrophils Infiltrate the Spinal Cord Parenchyma of Rats with Experimental Diabetic Neuropathy.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Diabetic | 2017 |
FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Diabetic | 2008 |
Gabapentin reverses microglial activation in the spinal cord of streptozotocin-induced diabetic rats.
Topics: Amines; Analgesics; Animals; Astrocytes; Cell Count; Cyclohexanecarboxylic Acids; Diabetes Mellitus, | 2009 |
Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Cyclopentanes; Diabetes Mellitus, Experime | 2009 |
Analysis of the antinociceptive interactions in two-drug combinations of gabapentin, oxcarbazepine and amitriptyline in streptozotocin-induced diabetic mice.
Topics: Administration, Oral; Amines; Amitriptyline; Analgesics; Animals; Behavior, Animal; Carbamazepine; C | 2010 |
Neuronal hyperactivity at the spinal cord and periaqueductal grey during painful diabetic neuropathy: effects of gabapentin.
Topics: Amines; Analgesics; Analysis of Variance; Animals; Cyclohexanecarboxylic Acids; Diabetes Mellitus, E | 2010 |
Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
Topics: Amines; Analgesics, Opioid; Animals; Carrageenan; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Ex | 2010 |
Pharmacological interaction between gabapentin and glibenclamide in the formalin test in the diabetic rat.
Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Drug Interactions; Ga | 2010 |
Protective effects of combined therapy of gliclazide with curcumin in experimental diabetic neuropathy in rats.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; C-Peptide; Curc | 2012 |
Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes.
Topics: Amines; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Dia | 2012 |
Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain.
Topics: Acetates; Amines; Animals; Benzofurans; Carbamates; Cyclohexanecarboxylic Acids; Diabetes Mellitus, | 2002 |
Reduction by gabapentin of K+-evoked release of [3H]-glutamate from the caudal trigeminal nucleus of the streptozotocin-treated rat.
Topics: Acetates; Amines; Animals; Blood Glucose; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experiment | 2004 |
Novel role for gabapentin in neuroprotection of central nervous system in streptozotocine-induced diabetic rats.
Topics: Amines; Animals; Brain; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Experimental; Gabapentin; ga | 2005 |
Adverse effects of gabapentin and lack of anti-allodynic efficacy of amitriptyline in the streptozotocin model of painful diabetic neuropathy.
Topics: Amines; Amitriptyline; Animals; Cognition Disorders; Cyclohexanecarboxylic Acids; Diabetes Mellitus, | 2006 |
Gabapentin prevents hyperalgesia during the formalin test in diabetic rats.
Topics: Acetates; Amines; Analgesics; Animals; Blood Glucose; Body Weight; Cyclohexanecarboxylic Acids; Diab | 1999 |
Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat.
Topics: Acetates; Amines; Amitriptyline; Analgesics; Animals; Cyclohexanecarboxylic Acids; Diabetes Mellitus | 1999 |